TY - JOUR
T1 - Liver-directed treatments for metastatic colorectal cancer
AU - Choti, Michael A.
N1 - Funding Information:
Michael A. Choti reports nonfinancial support from Bayer Healthcare and grants from BMS.
PY - 2014/9/1
Y1 - 2014/9/1
N2 - OPINION STATEMENT: When possible, surgical resection remains the "gold standard" for the treatment of hepatic colorectal metastases. Liver resection should be considered when complete removal of all macroscopic disease can be achieved safely. For those patients with unresectable metastases, or when a patient may not be a candidate for liver resection, many choices are available to the clinician in an attempt to achieve locoregional control, including tumor ablation, intra-arterial therapies, and radiation therapy. Whereas with surgical resection, durable local control can be considered potentially curable, other liver-directed approaches currently are mostly palliative. Ongoing trials are being undertaken to evaluate the role of such cytoreductive therapies. During the initial evaluation of any patient who might be a candidate for liver-directed therapy, particularly when the intent may be curative, complete assessment with high-quality imaging should be done before any therapy to determine the full extent of disease. Most importantly, the establishment of a multidisciplinary team upon initial diagnosis can optimize the choice and sequencing of the various systemic and locoregional choices available to the colorectal cancer patient.
AB - OPINION STATEMENT: When possible, surgical resection remains the "gold standard" for the treatment of hepatic colorectal metastases. Liver resection should be considered when complete removal of all macroscopic disease can be achieved safely. For those patients with unresectable metastases, or when a patient may not be a candidate for liver resection, many choices are available to the clinician in an attempt to achieve locoregional control, including tumor ablation, intra-arterial therapies, and radiation therapy. Whereas with surgical resection, durable local control can be considered potentially curable, other liver-directed approaches currently are mostly palliative. Ongoing trials are being undertaken to evaluate the role of such cytoreductive therapies. During the initial evaluation of any patient who might be a candidate for liver-directed therapy, particularly when the intent may be curative, complete assessment with high-quality imaging should be done before any therapy to determine the full extent of disease. Most importantly, the establishment of a multidisciplinary team upon initial diagnosis can optimize the choice and sequencing of the various systemic and locoregional choices available to the colorectal cancer patient.
UR - http://www.scopus.com/inward/record.url?scp=85027920862&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85027920862&partnerID=8YFLogxK
U2 - 10.1007/s11864-014-0297-1
DO - 10.1007/s11864-014-0297-1
M3 - Review article
C2 - 24952016
AN - SCOPUS:85027920862
VL - 15
SP - 456
EP - 464
JO - Current Treatment Options in Oncology
JF - Current Treatment Options in Oncology
SN - 1527-2729
IS - 3
ER -